Lisata Therapeutics (NASDAQ:LSTA – Get Rating) is one of 19 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it contrast to its competitors? We will compare Lisata Therapeutics to related companies based on the strength of its risk, institutional ownership, analyst recommendations, dividends, profitability, earnings and valuation.
Volatility & Risk
Lisata Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Lisata Therapeutics’ competitors have a beta of 4.01, suggesting that their average stock price is 301% more volatile than the S&P 500.
Valuation and Earnings
This table compares Lisata Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Lisata Therapeutics||N/A||-$27.47 million||-0.30|
|Lisata Therapeutics Competitors||$2.97 billion||$132.19 million||10.38|
This table compares Lisata Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Lisata Therapeutics Competitors||-2,169.68%||-132.55%||-27.24%|
Insider and Institutional Ownership
15.6% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 2.2% of Lisata Therapeutics shares are held by insiders. Comparatively, 23.9% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Lisata Therapeutics and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Lisata Therapeutics Competitors||32||247||370||31||2.59|
Lisata Therapeutics currently has a consensus target price of $15.00, indicating a potential upside of 314.36%. As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 81.75%. Given Lisata Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than its competitors.
Lisata Therapeutics competitors beat Lisata Therapeutics on 8 of the 13 factors compared.
Lisata Therapeutics Company Profile
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.